NEW EXPANSION IN CONTROLLED RELEASE TYPE DRUG DELIVERY SYSTEM

Chandrakant Mod, Chanchal Mali, Vishal Sharma

Abstract


To provide simple know-how and number one era in issuer drug shipping gadget and nanoparticles used in drug delivery. Efforts to confront disease dates back to early civilization. New drug candidates are tested even today in the quest to add increasingly effective tools against diseases Carrier-mediated drug delivery has emerged as a robust methodology for the treatment of varied pathologies. The therapeutic index of ancient and novel medicine is increased via the rise of specificity as a result of targeting of medicine to aselected tissue compartment, the control over release kinetics. Nanoparticles were proposed as drug carriers over 30 years ago and had Processing Rewrite Suggestions Done (Unique Article) received growing attention since, mainly due to their stability, increased loading capabilities and management over chemical science properties. The distinctive pathophysiology of solid tumors permits thepassive accumulation of NPs at these sites upon injection.

 


Keywords


Targeting, Carriers, Liposomes, Niosomes, Microspheres, Endocytosis

Full Text:

1-9

References


M. Ferrari Cancer nanotechnology: opportunities and challenges Nature Reviews Cancer 5 2005 161-171

T.M. Allen and P.R. Cullis Drug Delivery Systems: Entering the Mainstream Science 303 2004 1818-1822

K. Kostarelos Rational design and engineering of delivery systems for therapeutics:biomedical exercises in colloid and surface science Adv. Colloid Interface Sci. 106 2003 147-168

S.M. Moghimi, et al. Nanomedicine: current status and future prospects The FASEB Journal 19 2005 311-330

S.M. Moghimi and J. Szebeni Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties Progress in Lipid Research 42 2003 463-478

S.M. Moghimi, et al. Long-Circulating and Target-Specific Nanoparticles: Theory to Practice. Pharmacol Rev 53 2001 283-318

S.M. Moghimi and B. Bonnemain Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: Applications in lymphoscintigraphy and indirect lymphography Adv. Drug Delivery Rev. 37 1999 295-312

S.M. Moghimi Exploiting bone marrow microvascular structure for drug delivery and future therapies Adv. Drug Delivery Rev. 17 1995 61-73

M. Luck, et al. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J. Biomed. Mater. Res. 39 1998 478-485

V. Olivier, et al. Uptake of polystyrene beads bearing functional groups by macrophages and fibroblasts Coll. Surf. B Biointerf. 33 2004 23-31

R. Gref, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption Coll. Surf. B Biointerf. 18 2000 301-313

H. Otsuka, et al. PEGylated nanoparticles for biological and pharmaceutical applications Adv. Drug Delivery Rev. 55 2003 403-419

F. De Jaeghere, et al. Cellular uptake of PEO surface-modified nanoparticles: Evaluation of nanoparticles made of PLA : PEO diblock and triblock copolymers J. Drug Targeting 8 2000 143-153

S.M. Moghimi and A.C. Hunter Poloxamers and poloxamines in nanoparticles engineering and experimental medicine. Trends Biotechnol. 18 2000 412-420

J.K. Gbadamosi, et al. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance FEBS Lett. 532 2002 338-344

P.-A. Oldenborg, et al. Role of CD47 as a Marker of Self on Red Blood Cells Science 288 2000 2051-2054

Y.C. Hsu, et al. Reduced Phagocytosis of Colloidal Carriers Using Soluble CD47 Pharm.Res. 21 2003 1539-1542

M.A. Moses, et al. Advancing the field of drug delivery: Taking aim at cancer Cancer Cell 4 2003 337-341

E. Ruoslahti Specialization of tumour vasculature Nature Reviews Cancer 2 2002 83-90

H. Maeda, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics J. Controlled Release 65 2000 271-284

H. Hashizume, et al. Openings between defective endothelial cells explain tumor vessel leakiness Am. J. Pathol. 156 2000 1363-1380

D. Feng, et al. Ultrastructural Studies Define Soluble Macromolecular, Particulate, and Cellular Transendothelial Cell Pathways in Venules, Lymphatic Vessels, and Tumor-Associated Microvessels in Man and Animals Microscopy Research and Technique 57 2002 289-326

S.K. Hobbs, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment P. Natl. Acad. Sci. USA 95 1998 4607-4612

Y. Bae, et al. Preparation and Biological Characterization of Polymeric Micelle Drug Carriers with Intracellular pH-Triggered Drug Release Property: Tumor Permeability, Controlled Subcellular Drug Distribution, and Enhanced in Vivo Antitumor Efficacy Bioconjugate Chem. 16 2005 122-130

T.M. Allen Ligand-Targeted Therapeutics in Anticancer Therapy Nature Reviews Cancer 2 2002 750-763

N. Dinauer, et al. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes Biomaterials 26 2005 5898-5906

K. Na, et al. Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system Eur. J. Pharm. Sci. 18 2003 165-173

A. Fahr, et al. A new colloidal lipidic system for gene therapy Journal of Liposome Research 12 2002 37-44

C.P. Leamon and J.A. Reddy Folate-targeted chemotherapy Adv. Drug Delivery Rev. 56 2004 1127-1141

S.K. Sahoo and V. Labhasetwar Enhanced Antiproliferative Activity of Transferrin Conjugated Paclitaxel-Loaded Nanoparticles is Mediated via Sustained Intracellular Drug Retention Molecular Pharmaceutics 2005

L. Nobs, et al. Current Methods for Attaching Targeting Ligands to Liposomes and Nanoparticles J. Pharm. Sci. 93 2004 1980-1992

V.P. Torchilin, et al. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors Proceeding of the National Academy of Sciences 98 2001 8786-8791

J. Gruenberg The endocytic pathway: a mosaic of domains Nature Reviews Molecular Cell Biology 2 2001 721-730

K.D. Jensen, et al. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules J. Controlled Release 87 2003 89-105

D. Trentin, et al. Non-viral gene delivery for local and controlled DNA release J. Controlled Release 102 2005 263-275

N. Murthy, et al. A macromolecular delivery vehicle for protein-based vaccines: Acid degradable protein-loaded microgels P. Natl. Acad. Sci. USA 100 2003 4995-5000

E.R. Gillies and J.M.J. Frechet pH-Responsive Copolymer Assemblies for Controlled Release of Doxorubicin Bioconjugate Chem. 16 2005 361-368

I. Green, et al. Protein transduction domains: are they delivering? Trends Pharmacol. Sci. 24 2003 213-215

J.S. Wadia, et al. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft micropinocytosis Nat. Med. 10 2004 310-315

P. Watson, et al. Intracellular trafficking pathways and drug delivery: fluorescence imaging of living and fixed cells Adv. Drug Delivery Rev. 57 2005 43-61

F. Arcamone, et al. Adriamycin, 14-Hydroxydaunomycin, a New Antitumor Antibiotic from S. peucetius var. caesius Biotechnol. Bioeng. 11 1969 1101-1110

J.W. Park Liposome-based drug delivery in breast cancer treatment Breast Cancer Research 4 2002 95-99

A. Gabizon, et al. Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies Clin. Pharmacokinet. 42 2003 419-436

K.J. Harrington, et al. Liposomes as Vehicles for Targeted Therapy of Cancer. Part 2:Clinical Development Clinical Oncology 12 2000 16-24

J. Panyam and V. Labhasetwar Biodegradable nanoparticles for drug and gene delivery to cells and tissue Advanced Drug Delivery Reviews 55 2003 329-347

K.S. Soppimath, et al. Biodegradable polymeric nanoparticles as drug delivery devices J. Controlled Release 70 2001 1-20

I. Brigger, et al. Nanoparticles in cancer therapy and diagnosis Adv. Drug Delivery Rev. 54 2002 631-651

X. Xia, et al. Physically bonded nanoparticle networks: a novel drug delivery system J. Controlled Release 103 2005 21-30

A. Nori and J. Kopecek Intracellular targeting of polymer-bound drugs for cancer chemotherapy Adv. Drug Delivery Rev. 57 2005 609-636

F. Aulenta, et al. Dendrimers: a new class of nanoscopic containers and delivery devices European Polymer Journal 39 2003 1741-1771

M. Adams, et al. Amphiphilic Block Copolymers for Drug Delivery J. Pharm. Sci. 92 2003 1343-1355

D.E. Discher and A. Eisenberg Polymer vesicles Science 297 2002 967-973

V.C.F. Mosqueira, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: Effects of PEG chain length and density Pharm. Res. 18 2001 1411-1419

V.C.F. Mosqueira, et al. Poly(D,L-lactide) nanocapsules prepared by a solvent isplacement process: Influence of the composition on physicochemical and structural J. Pharm. Sci. 89 2000 614-626

J. Kreuter Evaluation of nanoparticles as drug delivery systems I: preparation methods Pharmaceutica Acta Helvetiae 58 1983 196-209

J.J. Marty, et al. Nanoparticles - New Colloidal Drug Delivery System Pharmaceutica Acta Helvetiae 53 1978 17-23

C. Vauthier, et al. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications Adv. Drug Delivery Rev. 55 2003 519-548

www.wikipediea.liposomes .com visited on 6/11/2017

Gregoriadis, G., The liposome drug carrier concept: its development and future. In Liposomes in Biological Systems, Gregoriadis, G. and Allison, A.C. ,Eds., John Wiley & Sons, New York. Also see Liposome Technology, Gregoriadis, G. Vol. 1–3, CRC Press, Inc., Boca Raton, FL, 1980.

Papahadjopoulos, D., Liposomes as drug carriers, Annu. Rep. Med. Chem. 14, 250–260, 1979.

www.wiki.niosomes visited on 10/11/2017

S.P. Vyas R.K. Khar,‘Targeted & controlled Drug Delivery’, novel carrier system CBS Publishers and Distributers Pvt. Ltd. Pune 7-8 2010


Refbacks

  • There are currently no refbacks.